REHOVOT, Israel - AgPlenus Ltd, a subsidiary of Evogene Ltd . (NASDAQ:EVGN) (TASE:EVGN), announced the appointment of Dr. Dan Jacob Gelvan as its new Chief Executive Officer, effective as of Sunday. Dr. Gelvan, with over 30 years of experience in the pharmaceutical, biotech, and healthcare sectors, is set to lead the company in its next growth phase.
Dr. Gelvan's career has encompassed roles from pre-clinical development to product launches, highlighting his leadership and strategic vision. His ability to secure funding and manage multicultural teams has been noted as a significant asset.
Concurrent with Dr. Gelvan's appointment, the former CEO, Dr. Brian Ember, will assume the role of Chief Business Officer. Dr. Ember's past contributions have been pivotal to AgPlenus' development, and he will continue to focus on strategic partnerships and business expansion.
Ofer Haviv, CEO of parent company Evogene and chairman of AgPlenus, expressed confidence in Dr. Gelvan's capabilities to steer AgPlenus towards innovative solutions in sustainable crop protection. Dr. Gelvan expressed his commitment to advancing AgPlenus' mission and creating value for stakeholders.
AgPlenus is known for its design of sustainable crop protection products, addressing global pesticide resistance. Utilizing the ChemPass AI tech-engine, licensed from Evogene, AgPlenus aims to discover and market new products with a target-based approach to reduce risk and increase efficiency.
Evogene is a computational biology company that has established three tech-engines – MicroBoost AI, ChemPass AI, and GeneRator AI – each focusing on microbes, small molecules, and genetic elements, respectively. These tech-engines are applied across Evogene's subsidiaries and strategic partnerships for product development in various life-science sectors.
This announcement is based on a press release statement. It should be noted that forward-looking statements involve risks and uncertainties, and actual results may differ materially from those projected. Evogene and its subsidiaries emphasize that they do not undertake any obligation to update these statements in light of new information or future events.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.